Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT04940026
- Locations
- 🇬🇧
Investigational Site Number 8260001, Nottingham, United Kingdom
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 106
- Registration Number
- NCT04914897
- Locations
- 🇮🇹
Investigational Site Number : 3800005, Aviano (PN), Friuli-Venezia Giulia, Italy
🇮🇹Investigational Site Number : 3800001, Rozzano, Milano, Italy
🇰🇷Investigational Site Number : 4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 46
- Registration Number
- NCT04913220
- Locations
- 🇫🇷
Investigational Site Number : 2500003, Bobigny, France
🇨🇱Investigational Site Number : 1520006, Antofagasta, Chile
🇦🇺Investigational Site Number : 0360001, Macquarie University, New South Wales, Australia
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT04910776
- Locations
- 🇺🇸
Stanford Hospital- Site Number : 8400006, Stanford, California, United States
🇺🇸Children's Minnesota- Site Number : 8400008, Minneapolis, Minnesota, United States
🇺🇸Advanced Medical Genetics- Site Number : 8400002, Hawthorne, New York, United States
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 129
- Registration Number
- NCT04879628
- Locations
- 🇧🇬
Investigational Site Number : 1000002, Pleven, Bulgaria
🇷🇺Investigational Site Number : 6430008, Tyumen, Russian Federation
🇷🇺Investigational Site Number : 6430001, Moscow, Russian Federation
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)
- Conditions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Sanofi
- Registration Number
- NCT04877132
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT04848779
- Locations
- 🇺🇸
Boston Children's Health Physicians Site Number : 8400002, Valhalla, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center - PIN Site Number : 8400001, Cincinnati, Ohio, United States
🇺🇸Seattle Childrens Hospital and Regional Medical Center Site Number : 8400003, Seattle, Washington, United States
A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen
- Conditions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT04845958
- Locations
- 🇫🇷
Investigational Site Number 2500034, Argenteuil, France
🇫🇷Investigational Site Number 2500036, Amiens, France
🇫🇷Investigational Site Number 2500014, Angers, France
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT04823130
- Locations
- 🇺🇸
Investigational Site Number 8400001, Miami, Florida, United States
🇺🇸Investigational Site Number 8400002, East Windsor, New Jersey, United States
🇩🇪Investigational Site Number 2760001, Münster, Germany
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 78
- Registration Number
- NCT04781816
- Locations
- 🇮🇳
Investigational Site Number : 3560002, Chandigarh, India
🇲🇽Investigational Site Number : 4840002, Veracruz, Mexico
🇺🇸ClinOhio Research Services Site Number : 8400007, Columbus, Ohio, United States